We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
Cap. Flow
-$834M
Cap. Flow %
-19.85%
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$203M
2
GILD icon
Gilead Sciences
GILD
+$156M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$146M
4
AMGN icon
Amgen
AMGN
+$98.7M
5
VRDN icon
Viridian Therapeutics
VRDN
+$70.3M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$350M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$235M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$225M
4
RNAM
Avidity Biosciences
RNAM
+$190M
5
FOLD
Amicus Therapeutics
FOLD
+$153M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Energy 0.07%
3 Technology 0.06%
4 Financials 0.03%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
26
Tango Therapeutics
TNGX
$4.25B
$50.2M 1.19%
2,400,000
-1,527,670
-39% -$21.3M
IDXX icon
27
Idexx Laboratories
IDXX
$43.4B
$50.1M 1.19%
89,131
-5,408
-6% -$3.47M
RARE icon
28
Ultragenyx Pharmaceutical
RARE
$2.59B
$49.9M 1.19%
2,380,000
+2,377,420
+92,148% +$53.5M
DXCM icon
29
DexCom
DXCM
$33.9B
$49.5M 1.18%
788,766
-58,639
-7% -$4.08M
JBIO
30
Jade Biosciences
JBIO
$1.58B
$49.2M 1.17%
3,501,502
+160,399
+5% +$2.32M
EWTX icon
31
Edgewise Therapeutics
EWTX
$4.76B
$48.1M 1.15%
1,528,518
– –
UNH icon
32
UnitedHealth
UNH
$360B
$40.1M 0.95%
148,203
-26,966
-15% -$8.03M
DHR icon
33
Danaher
DHR
$143B
$38.3M 0.91%
202,164
+7,531
+4% +$1.6M
CLDX icon
34
Celldex Therapeutics
CLDX
$3.28B
$38.1M 0.91%
1,200,000
-2,417,669
-67% -$65.9M
RMD icon
35
ResMed
RMD
$32.6B
$35.8M 0.85%
159,346
-1,868
-1% -$466K
PODD icon
36
Insulet
PODD
$9.98B
$34.3M 0.82%
163,656
-23,043
-12% -$5.79M
TMO icon
37
Thermo Fisher Scientific
TMO
$219B
$31.7M 0.75%
64,412
-665
-1% -$361K
LLY icon
38
Eli Lilly
LLY
$1.06T
$31.2M 0.74%
33,932
-71
-0.2% -$72K
GEHC icon
39
GE HealthCare
GEHC
$33.3B
$29.7M 0.71%
416,887
-7,627
-2% -$601K
IRON icon
40
Disc Medicine
IRON
$3.02B
$29.4M 0.7%
+459,314
New +$31.9M
JNJ icon
41
Johnson & Johnson
JNJ
$630B
$29.1M 0.69%
119,102
-7,698
-6% -$1.79M
ANNX icon
42
Annexon
ANNX
$865M
$28.6M 0.68%
5,157,290
– –
CI icon
43
Cigna
CI
$74.3B
$26.2M 0.62%
98,263
-11,750
-11% -$3.25M
ORKA
44
Oruka Therapeutics
ORKA
$7.22B
$24.9M 0.59%
+507,008
New +$17.6M
MRK icon
45
Merck
MRK
$334B
$24.9M 0.59%
206,591
+114,474
+124% +$13.2M
ALGN icon
46
Align Technology
ALGN
$12.8B
$23.9M 0.57%
139,680
-1,794
-1% -$314K
STE icon
47
Steris
STE
$22.8B
$22.1M 0.53%
99,878
-1,827
-2% -$447K
GMED icon
48
Globus Medical
GMED
$11.5B
$21.3M 0.51%
247,261
-15,422
-6% -$1.38M
GLUE icon
49
Monte Rosa Therapeutics
GLUE
$1.34B
$20.6M 0.49%
+1,250,000
New +$23.9M
ABBV icon
50
AbbVie
ABBV
$442B
$20.3M 0.48%
93,567
-41,292
-31% -$9.16M
1
2
3 4 5

Similar funds

SAMU
SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
BMO
Beck Mack & Oliver New York $4.85B AUM 9.66% 1-Year Est. Return

Bellevue Group's Q1 2026 Portfolio in Review

As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.

Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.

  • Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
  • Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
  • Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
  • Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
  • Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
  • Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
  • Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.